Table 4.

Compared proportions of MTD recommendation and accuracy measure for the optimal design and CRM-L after 10,000 simulated trials. The true MTD is indicated in bold type. The target toxicity rate is 30% and the fixed sample size for each trial is 25 patients. First stage cohort size is 2.

Dose	1	2	3	4	5	6	A(n)
Scenario 7	0.05	0.15	0.30	0.40	0.50	0.60
CRM-L (A)	0.00	0.16	0.46	0.28	0.09	0.01	0.564
CRM-L (B)	0.01	0.16	0.42	0.30	0.10	0.01	0.521
Optimal	0.00	0.18	0.55	0.23	0.05	0.00	0.641
Scenario 8	0.08	0.12	0.20	0.30	0.42	0.53
CRM-L (A)	0.00	0.05	0.24	0.42	0.24	0.05	0.482
CRM-L (B)	0.00	0.04	0.22	0.41	0.26	0.07	0.459
Optimal	0.00	0.03	0.25	0.47	0.21	0.03	0.552
Scenario 9	0.30	0.38	0.45	0.55	0.70	0.80
CRM-L (A)	0.63	0.26	0.10	0.01	0.00	0.00	0.829
CRM-L (B)	0.63	0.24	0.11	0.02	0.00	0.00	0.823
Optimal	0.65	0.25	0.09	0.01	0.00	0.00	0.842
Scenario 10	0.02	0.05	0.10	0.15	0.23	0.30
CRM-L (A)	0.00	0.00	0.01	0.10	0.29	0.59	0.758
CRM-L (B)	0.00	0.00	0.01	0.08	0.24	0.67	0.807
Optimal	0.00	0.00	0.01	0.08	0.31	0.60	0.771
Scenario 11	0.18	0.28	0.36	0.44	0.52	0.65
CRM-L (A)	0.19	0.38	0.27	0.12	0.03	0.00	0.534
CRM-L (B)	0.20	0.33	0.30	0.14	0.04	0.00	0.496
Optimal	0.20	0.40	0.27	0.10	0.02	0.00	0.546
Scenario 12	0.01	0.03	0.05	0.12	0.30	0.46
CRM-L (A)	0.00	0.00	0.00	0.14	0.54	0.32	0.598
CRM-L (B)	0.00	0.00	0.00	0.14	0.50	0.35	0.567
Optimal	0.00	0.00	0.00	0.12	0.71	0.17	0.745

Avg. A(n): CRM-L (A) = 0.628; CRM-L(B) = 0.612; Optimal = 0.684